---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:00.734854'
end_time: '2025-12-14T17:22:17.471234'
duration_seconds: 376.74
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PLD5
  gene_symbol: PLD5
  uniprot_accession: Q8N7P1
  protein_description: 'RecName: Full=Inactive phospholipase D5; Short=Inactive PLD
    5; AltName: Full=Inactive choline phosphatase 5; AltName: Full=Inactive phosphatidylcholine-hydrolyzing
    phospholipase D5; AltName: Full=PLDc;'
  gene_info: Name=PLD5;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the phospholipase D family. .
  protein_domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase.
    (IPR001736); PLDc_3 (PF13918)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 14
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8N7P1
- **Protein Description:** RecName: Full=Inactive phospholipase D5; Short=Inactive PLD 5; AltName: Full=Inactive choline phosphatase 5; AltName: Full=Inactive phosphatidylcholine-hydrolyzing phospholipase D5; AltName: Full=PLDc;
- **Gene Information:** Name=PLD5;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD5** (gene ID: PLD5, UniProt: Q8N7P1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8N7P1
- **Protein Description:** RecName: Full=Inactive phospholipase D5; Short=Inactive PLD 5; AltName: Full=Inactive choline phosphatase 5; AltName: Full=Inactive phosphatidylcholine-hydrolyzing phospholipase D5; AltName: Full=PLDc;
- **Gene Information:** Name=PLD5;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD5** (gene ID: PLD5, UniProt: Q8N7P1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Verify identity, organism, and family/domain membership for human PLD5 (Q8N7P1).
- Extract PLD5-specific evidence on catalytic motifs/activity, subcellular localization, tissue expression (esp. brain), molecular roles/pathways, regulation, and disease associations.
- Prioritize recent (2023–2024) reviews for PLD family context and reconcile any conflicting annotations on PLD5.
- Synthesize applications/implementations, expert opinions, and quantitative findings where available; clearly state unknowns.
- Provide a fully cited research report with URLs and publication dates.

Comprehensive Research Report: Human PLD5 (UniProt Q8N7P1)

Gene/protein verification and family placement
- Identity and organism: The target is human PLD5 (phospholipase D family member 5), UniProt Q8N7P1, in Homo sapiens. Multiple authoritative reviews place PLD5 within the mammalian phospholipase D (PLD) superfamily that comprises PLD1–PLD6 (review context, human-focused) (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3). A biochemical review of “pseudo-PLD” domains also summarizes the human PLD family membership (Jun 2018; https://doi.org/10.1042/BST20160277) (bozatzi2018thefam83family pages 1-2).
- Domain/family alignment: PLD family members characteristically harbor HKD catalytic motifs (HXKX4D), typically in two copies, and fall within the broader PLD superfamily fold (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3). Reviews covering PLD family architecture include PLD5 in the six-member human set and discuss HKD motif presence/absence as a key functional discriminator (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Key concepts and definitions (current understanding)
- Canonical PLD reaction: Active phospholipase D enzymes hydrolyze phosphatidylcholine to choline and phosphatidic acid (PA). In the presence of primary alcohols, they catalyze transphosphatidylation to form phosphatidylalcohols, a property exploited to measure PLD activity in cells (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3).
- PLD5 catalytic status: Authoritative reviews consistently report that human PLD5 lacks catalytic activity as a lipase because it lacks the requisite conserved HKD catalytic motifs; thus PLD5 is considered catalytically inactive within the classical PLD reaction framework (Jun 2018; https://doi.org/10.1042/BST20160277; Dec 2015; https://doi.org/10.1194/jlr.R059220) (bozatzi2018thefam83family pages 1-2, nelson2015physiologicalandpathophysiological pages 1-3).
- Family nuance: Recent PLD superfamily overviews emphasize that not all HKD-containing proteins are catalytically active phospholipases; some paralogs (e.g., PLD3) possess nuclease activity rather than phospholipase activity, underscoring divergent functions within the family and cautioning against motif-only inference (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Domain architecture and catalytic motifs
- HKD motifs: PLD catalytic function generally requires two HKD motifs within a single polypeptide. PLD5 is described as lacking these motifs and therefore being catalytically inactive as a phospholipase (Jun 2018; https://doi.org/10.1042/BST20160277; Dec 2015; https://doi.org/10.1194/jlr.R059220) (bozatzi2018thefam83family pages 1-2, nelson2015physiologicalandpathophysiological pages 1-3).
- Reconciling literature: A 2024 review catalogs PLD family members and summarizes that HKD motif presence does not guarantee activity, and that some isoforms are HKD-containing but catalytically inactive or may lack one subdomain; however, it does not present experimental phospholipase activity for PLD5, and it aligns with earlier consensus that PLD5 has not been validated as an active phospholipase (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Catalytic activity (experimental evidence)
- No confirmed phospholipase activity: Reviews explicitly state PLD5 has “no catalytic activity” as a lipase (Dec 2015; https://doi.org/10.1194/jlr.R059220) and “is catalytically inactive” due to lacking HKD motifs (Jun 2018; https://doi.org/10.1042/BST20160277) (nelson2015physiologicalandpathophysiological pages 1-3, bozatzi2018thefam83family pages 1-2).
- Non-lipase activities: While other PLD family members (e.g., PLD3) have been demonstrated to have nuclease activity rather than phospholipase activity, there is currently no specific experimental demonstration of an alternative enzymatic activity for PLD5 (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Cellular/subcellular localization and tissue expression
- Subcellular localization: Specific subcellular localization of human PLD5 has not been resolved in the curated reviews used here. In contrast, PLD3/PLD4 are type II transmembrane proteins in the secretory pathway and PLD6 is mitochondrial, but comparable experimental localization for PLD5 was not reported (Jun 2018; https://doi.org/10.1042/BST20160277) (bozatzi2018thefam83family pages 1-2).
- Tissue expression: Definitive, experimentally supported tissue expression patterns for PLD5 (e.g., GTEx brain enrichment) were not identified in the retrieved, citable sources. Some studies discuss PLD5 in disease-tissue contexts (see below), but broad quantitative normal-tissue expression remains insufficiently characterized in the present evidence set (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3).

Molecular function and pathways
- Given lack of confirmed phospholipase activity, PLD5’s molecular function remains incompletely defined. By family context, PLD proteins (active isoforms) generate PA, influencing membrane dynamics, vesicle trafficking, and signaling; however, there is no direct evidence that PLD5 participates in PA signaling as a catalytic source of PA (Dec 2015; https://doi.org/10.1194/jlr.R059220; Jun 2018; https://doi.org/10.1042/BST20160277) (nelson2015physiologicalandpathophysiological pages 1-3, bozatzi2018thefam83family pages 1-2).
- Emerging view from recent reviews: The 2024 review reiterates divergent functions within the PLD family and highlights the caution that assignment of catalytic roles to lesser-characterized members like PLD5 should await direct biochemical/functional data (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Regulation and disease associations
- Cancer regulation by miRNA: A primary study in human prostate cancer demonstrates that miR-145-5p directly targets PLD5 (3′ UTR reporter validation). In prostate cancer cell lines and xenograft models, PLD5 overexpression promotes proliferation, migration, invasion, and metastasis, whereas miR-145-5p mimics suppress these PLD5-driven oncogenic phenotypes and increase apoptosis. This establishes post-transcriptional regulation of PLD5 by miR-145-5p and supports a pro-tumorigenic role of PLD5 expression in this context (Jan 2021; https://doi.org/10.1080/21655979.2021.1945361) (liu2021micrornamir1455pinhibits pages 1-3, liu2021micrornamir1455pinhibits pages 3-5).
- Human genetic associations: Earlier review summarizing human studies notes PLD5 polymorphisms associated with tumor progression risk in cutaneous and uterine leiomyomatosis, and a borderline association signal for autism spectrum disorder in a genotyping study of 1,558 families—interpreted as suggestive and requiring further validation (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3, nelson2015physiologicalandpathophysiological pages 10-12).

Recent developments and latest research (2023–2024 emphasis)
- Family-level insights: A 2024 review of PLD in neurodegenerative and neuroimmune diseases underscores that the human PLD family contains catalytically diverse members and that some paralogs lack or diverge in HKD motifs; this review continues to list PLD5 as a poorly characterized family member without validated phospholipase activity, highlighting the need for direct functional studies (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).
- Implications from related family members: The recognition that PLD3 acts as a nuclease rather than a phospholipase refocuses attention on noncanonical roles within the family and cautions against motif-based assumptions for PLD5, but no new 2023–2024 experimental activity/localization data specific to PLD5 were identified in our evidence set (Mar 2024; https://doi.org/10.1155/2024/6681911) (zhang2024phospholipaseda pages 1-2).

Current applications and real-world implementations
- Oncology research: The miR-145-5p—PLD5 axis in prostate cancer offers a potential therapeutic angle (restoring miR-145-5p or inhibiting PLD5 expression/function) that reduced proliferation/metastasis in preclinical models, though no clinical trials targeting PLD5 were found in the present evidence (Jan 2021; https://doi.org/10.1080/21655979.2021.1945361) (liu2021micrornamir1455pinhibits pages 1-3, liu2021micrornamir1455pinhibits pages 3-5).
- PLD inhibitors: While small-molecule PLD inhibitors exist and are under development (largely targeting PLD1/PLD2), there is no evidence of catalytic inhibition strategies being applicable to PLD5 specifically, given the lack of confirmed enzymatic activity (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 1-3).

Expert opinions, analysis, and consensus
- Consensus on inactivity: Cross-review agreement (2015, 2018) supports PLD5 as catalytically inactive due to lacking HKD motifs. The most recent 2024 review maintains PLD5 as insufficiently characterized and does not overturn the inactivity consensus, instead emphasizing the broader functional diversity in the family and the need for direct testing (Dec 2015; https://doi.org/10.1194/jlr.R059220; Jun 2018; https://doi.org/10.1042/BST20160277; Mar 2024; https://doi.org/10.1155/2024/6681911) (nelson2015physiologicalandpathophysiological pages 1-3, bozatzi2018thefam83family pages 1-2, zhang2024phospholipaseda pages 1-2).
- Disease implications remain preliminary: Genetic associations summarized in review literature are suggestive but not definitive; the clearest experimental disease relevance to date is the miR-145-5p–PLD5 axis in prostate cancer models (Dec 2015; https://doi.org/10.1194/jlr.R059220; Jan 2021; https://doi.org/10.1080/21655979.2021.1945361) (nelson2015physiologicalandpathophysiological pages 10-12, liu2021micrornamir1455pinhibits pages 1-3, liu2021micrornamir1455pinhibits pages 3-5).

Relevant statistics and data
- Prostate cancer models: The 2021 study reports significant suppression of proliferation/migration/invasion upon miR-145-5p overexpression and reversal of PLD5 overexpression phenotypes in vitro and inhibition of metastasis in vivo; the study validates direct binding via dual-luciferase reporters containing the PLD5 3′ UTR (Jan 2021; https://doi.org/10.1080/21655979.2021.1945361) (liu2021micrornamir1455pinhibits pages 1-3, liu2021micrornamir1455pinhibits pages 3-5). (Note: The study is experimental and provides effect-size data in figures; the qualitative summary here is derived from the reported results.)
- Human genetics: Association signals for PLD5 polymorphisms with leiomyomatosis progression and borderline ASD association are summarized in review form and should be interpreted cautiously pending replication (Dec 2015; https://doi.org/10.1194/jlr.R059220) (nelson2015physiologicalandpathophysiological pages 10-12).

Gaps and recommendations
- Localization and expression: Robust, direct data for human PLD5 subcellular localization and normal tissue expression (e.g., brain enrichment) were not found in the curated sources here; further targeted searches of proteomic localization atlases and GTEx/brain transcriptomics with orthogonal validation are recommended.
- Function: Given the absence of demonstrated phospholipase activity, targeted biochemical assays for alternative activities (e.g., nucleic acid metabolizing) or nonenzymatic roles, along with cellular phenotyping upon knockdown/overexpression, are priorities.
- Disease relevance: Beyond prostate cancer models, systematic interrogation of PLD5 expression/regulation across cancers and neurodevelopmental/neuropsychiatric conditions (with replication and mechanistic follow-up) is needed.

Conclusion
Human PLD5 (Q8N7P1) is a poorly characterized member of the PLD superfamily. Consensus reviews indicate it lacks the HKD catalytic motifs necessary for phospholipase activity and is therefore considered catalytically inactive as a lipase. No definitive subcellular localization or normal-tissue expression atlas could be confirmed in the present evidence. The clearest experimental evidence for biological relevance is in prostate cancer, where miR-145-5p directly targets PLD5 and suppresses PLD5-driven oncogenic phenotypes in vitro and in vivo. Family-level advances in 2024 underscore functional diversity among PLD paralogs but do not provide new PLD5-specific functional activity. Overall, PLD5 remains an understudied protein with suggestive disease links that warrant targeted experimental characterization (Dec 2015; https://doi.org/10.1194/jlr.R059220; Jun 2018; https://doi.org/10.1042/BST20160277; Mar 2024; https://doi.org/10.1155/2024/6681911; Jan 2021; https://doi.org/10.1080/21655979.2021.1945361) (nelson2015physiologicalandpathophysiological pages 1-3, bozatzi2018thefam83family pages 1-2, zhang2024phospholipaseda pages 1-2, liu2021micrornamir1455pinhibits pages 1-3, liu2021micrornamir1455pinhibits pages 3-5, nelson2015physiologicalandpathophysiological pages 10-12).

References

1. (nelson2015physiologicalandpathophysiological pages 1-3): Rochelle K. Nelson and Michael A. Frohman. Physiological and pathophysiological roles for phospholipase d. Journal of Lipid Research, 56:2229-2237, Dec 2015. URL: https://doi.org/10.1194/jlr.r059220, doi:10.1194/jlr.r059220. This article has 125 citations and is from a peer-reviewed journal.

2. (bozatzi2018thefam83family pages 1-2): Polyxeni Bozatzi and Gopal P. Sapkota. The fam83 family of proteins: from pseudo-plds to anchors for ck1 isoforms. Biochemical Society Transactions, 46:761-771, Jun 2018. URL: https://doi.org/10.1042/bst20160277, doi:10.1042/bst20160277. This article has 54 citations and is from a peer-reviewed journal.

3. (zhang2024phospholipaseda pages 1-2): Weiwei Zhang, Feiqi Zhu, Jie Zhu, and Kangding Liu. Phospholipase d, a novel therapeutic target contributes to the pathogenesis of neurodegenerative and neuroimmune diseases. Analytical Cellular Pathology (Amsterdam), Mar 2024. URL: https://doi.org/10.1155/2024/6681911, doi:10.1155/2024/6681911. This article has 6 citations.

4. (liu2021micrornamir1455pinhibits pages 1-3): Juanni liu, Junhai Li, Yongtu Ma, Changbao Xu, Yigang Wang, and Yanfeng He. Microrna mir-145-5p inhibits phospholipase d 5 (pld5) to downregulate cell proliferation and metastasis to mitigate prostate cancer. Bioengineered, 12:3240-3251, Jan 2021. URL: https://doi.org/10.1080/21655979.2021.1945361, doi:10.1080/21655979.2021.1945361. This article has 33 citations.

5. (liu2021micrornamir1455pinhibits pages 3-5): Juanni liu, Junhai Li, Yongtu Ma, Changbao Xu, Yigang Wang, and Yanfeng He. Microrna mir-145-5p inhibits phospholipase d 5 (pld5) to downregulate cell proliferation and metastasis to mitigate prostate cancer. Bioengineered, 12:3240-3251, Jan 2021. URL: https://doi.org/10.1080/21655979.2021.1945361, doi:10.1080/21655979.2021.1945361. This article has 33 citations.

6. (nelson2015physiologicalandpathophysiological pages 10-12): Rochelle K. Nelson and Michael A. Frohman. Physiological and pathophysiological roles for phospholipase d. Journal of Lipid Research, 56:2229-2237, Dec 2015. URL: https://doi.org/10.1194/jlr.r059220, doi:10.1194/jlr.r059220. This article has 125 citations and is from a peer-reviewed journal.

## Citations

1. nelson2015physiologicalandpathophysiological pages 1-3
2. zhang2024phospholipaseda pages 1-2
3. nelson2015physiologicalandpathophysiological pages 10-12
4. https://doi.org/10.1194/jlr.R059220
5. https://doi.org/10.1042/BST20160277
6. https://doi.org/10.1155/2024/6681911
7. https://doi.org/10.1042/BST20160277;
8. https://doi.org/10.1194/jlr.R059220;
9. https://doi.org/10.1080/21655979.2021.1945361
10. https://doi.org/10.1155/2024/6681911;
11. https://doi.org/10.1194/jlr.r059220,
12. https://doi.org/10.1042/bst20160277,
13. https://doi.org/10.1155/2024/6681911,
14. https://doi.org/10.1080/21655979.2021.1945361,